Dr. Michael Seiden, MD, PhD, serves as a board member and senior strategic advisor for REV Clinical, bringing decades of translational research, oncology, and clinical development leadership to the organization. He previously held leadership roles in academia, biotech, and large pharmaceutical organizations, guiding the development of novel therapies from discovery through late-stage clinical trials. His deep experience in cancer biology, clinical trial design, and regulatory science has informed groundbreaking programs and collaborations across institutions. Dr. Seiden earned his MD and PhD in immunology from Washington University in St. Louis and a BA in Chemistry from Oberlin College.